Abstract | BACKGROUND: METHODS: From July 1995 through February 1997, 34 patients with advanced thymoma or thymic carcinoma were entered on trial to receive etoposide (75 mg/m2 on Days 1-4) ifosfamide (1.2 g/m2 on Days 1-4), and cisplatin (20 mg/m2 on Days 1-4). Cycles were repeated every 3 weeks for four total cycles. RESULTS: Among 28 evaluable patients (pathology review excluded 6 patients), there were no complete responses and 9 partial responses (complete and partial responses combined, 32%; 95% confidence interval, 16-52%). The median follow-up was 43 months (range, 12.8-52.3 months), the median duration of response was 11.9 months (range, < 1-26 months), and the median overall survival was 31.6 months. Based on Kaplan-Meier estimates, the 1-year and 2-year survival rates were 89% and 70%, respectively. The toxicity was predominantly myelosuppression. CONCLUSIONS: The VIP regimen has moderate activity in patients with advanced thymic malignancies. However, with limited follow-up, the results of this trial appear to be inferior to other chemotherapy regimens reported in large Phase II trials performed in patients with this disease.
|
Authors | P J Loehrer Sr, M Jiroutek, S Aisner, J Aisner, M Green, C R Thomas Jr, R Livingston, D H Johnson |
Journal | Cancer
(Cancer)
Vol. 91
Issue 11
Pg. 2010-5
(Jun 01 2001)
ISSN: 0008-543X [Print] United States |
PMID | 11391579
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2001 American Cancer Society. |
Chemical References |
- Etoposide
- Cisplatin
- Ifosfamide
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Cisplatin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Male
- Middle Aged
- Survival Analysis
- Thymoma
(drug therapy, pathology)
- Thymus Neoplasms
(drug therapy, pathology)
- Treatment Outcome
|